US › Healthcare

Rani Therapeutics Holdings Inc (RANI)

US · Healthcare · Biotechnology

$0.82+2.33%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.7M
Revenue YoY
+893.0%
Net profit
$-7.0M
Profit YoY
+3.2%
EPS
$-0.04
EPS estimate
$-0.04
Net margin
-411.8%

EPS came in at -0.04 against a street estimate of -0.04 — a beat of 0.0%.

Key statistics

Market cap
$106.4M
Forward P/E
0.0
P/B
3.08
Book value
$0.28
EPS (TTM)
$-0.27
52-week high
$3.87
52-week low
$0.44
50-day MA
$0.81
200-day MA
$1.21
Beta
0.80

Analyst view

Analysts rate Rani Therapeutics Holdings Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $7.50.

Shareholding

Insiders
5.04%
Institutions
43.91%

Largest institutional holders

FundStake
RA Capital Management, LLC8.52%
Samsara BioCapital, LLC8.52%
Awm Investment Company Inc6.51%
Vanguard Capital Management, LLC4.63%
SymBiosis Capital Partners, LLC3.67%
Longaeva Partners L.P.2.33%
Siren, L.L.C.2.00%
Geode Capital Management, LLC0.91%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rani Therapeutics Holdings Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.